Neimeth International Pharmaceuticals Plc (NGX:NEIMETH)

NGX:NEIMETH Financials Overview

Financials in millions NGN. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Sep 30, 2022
Revenue Revenue Growth	7,914	7,369	4,485	2,210	2,919	2,703
Revenue Growth	56.92%	64.29%	102.98%	-24.31%	8.01%	-11.29%
Gross Profit Gross Profit Growth	3,215	3,033	1,936	709.15	1,033	1,074
Operating Income Operating Income Growth	2,320	2,169	1,832	298.73	-12.39	-24.8
Net Income Net Income Growth	984.32	976.42	-885.33	-1,798	-325.04	-109.66
Earnings Per Share EPS Growth	0.23	0.23	-0.21	-0.42	-0.17	-0.06
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Sep 30, 2022
Pharmaceuticals Pharmaceuticals Growth	7,704	7,181	4,301	2,067	2,844	2,635
Animal Health Animal Health Growth	209.55	187.55	184.26	142.84	75.09	67.38
Total Total Growth	7,914	7,369	4,485	2,210	2,919	2,703

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Sep 30, 2022
Cash & Investments Cash & Investments Growth	1,677	1,555	2,147	2,429	448.37	810.49
Total Debt Total Debt Growth	9,513	9,618	5,385	4,388	3,645	3,331
Net Cash (Debt) Net Cash Growth	-7,836	-8,063	-3,238	-1,959	-3,197	-2,521
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share Net Cash Per Share Growth	-1.83	-1.89	-0.76	-0.46	-1.68	-1.33

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Sep 30, 2022
Operating Cash Flow Operating Cash Flow Growth	1,817	1,507	396.21	-773.41	132.55	-61.76
Capital Expenditures CapEx Growth	-310.3	-278.23	-702.92	-936.14	-1,270	-1,143
Free Cash Flow Free Cash Flow Growth	1,507	1,229	-306.71	-1,710	-1,137	-1,205
Free Cash Flow Growth	656.51%	-	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Sep 30, 2022
Gross Margin	40.62%	41.16%	43.16%	32.09%	35.39%	39.74%
Operating Margin	29.32%	29.44%	40.84%	13.52%	-0.43%	-0.92%
Pretax Margin	16.74%	17.82%	-19.05%	-76.47%	-10.63%	-4.06%
Profit Margin	12.44%	13.25%	-19.74%	-81.35%	-11.13%	-4.06%
FCF Margin	19.04%	16.68%	-6.84%	-77.37%	-38.95%	-44.57%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Jul 25, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Sep 30, 2022
PE Ratio	39.94	25.38	-	-	-	-
P/FCF Ratio	26.09	20.16	-	-	-	-
PS Ratio	4.97	3.36	2.18	3.75	0.93	0.98

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 25, 2026

Data Sources Report a data error